来自官方财务报表的收入、利润与现金流历史。
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | JPY 500.0B | JPY 508.6B | JPY 461.5B | JPY 410.5B | — |
| 毛利 | JPY 255.7B | JPY 272.0B | JPY 242.5B | JPY 216.1B | — |
| 营业利润（EBIT） | JPY 63.4B | JPY 90.8B | JPY 80.6B | JPY 76.0B | — |
| 净利 | JPY 35.5B | JPY 53.7B | JPY 49.6B | JPY 45.8B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 6869 交互式查看器。 /companies/us/6869
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms